Casandra
Casandra Test Code QD20982Version 1 (DRAFT)
Performing Lab
Alpha-Fetoprotein (AFP) and AFP‑L3
Clinical Use
Order TestUse
This assay is intended for use in the assessment of risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
AFP‑L3
ProteinAFP‑L3 • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
Alpha‑Fetoprotein
ProteinAFP • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Serum
Volume
Not provided
Minimum Volume
0.5 mL
Container
Serum separator tube or plain red tube; centrifuge and aliquot 1.5 mL serum
Collection Instructions
Centrifuge SST; if plain red, centrifuge and aliquot serum
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient: 72 hours |
| Refrigerated | 5 days |
| Frozen | 2 years |
Related Tests
Other tests from different labs that may be relevant
α-Fetoprotein (AFP) With AFP-L3%
Labcorp
Alpha Fetoprotein, Total and L3 Percent
ARUP Laboratories
Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum
Mayo Clinic Lab
Hepatocellular Carcinoma Tumor Marker Panel
ARUP Laboratories
α-Fetoprotein (AFP) With AFP-L3% (Serial Monitor)
Labcorp
Alpha Fetoprotein, Serum (Tumor Marker)
ARUP Laboratories
Alpha-Fetoprotein (AFP) Tumor Marker, Serum
Mayo Clinic Lab
α-Fetoprotein (AFP), Tumor Marker
Labcorp
α-Fetoprotein (AFP), Tumor Marker (Serial Monitor)
Labcorp
Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
Mayo Clinic Lab